Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib in PIK3CA-Mutant, HR+, HER2- Advanced Breast Cancer
NCT04191499Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Inavolisib + Palbociclib + Fulvestrant with Placebo + Palbociclib + Fulvestrant (2 arms). Primary endpoint: Progression-Free Survival up to 3.7 years. Started Jan 2020; status: active, not recruiting.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04191499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191499.